On August 30, 2018 Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, reported that Steven A. Shallcross, Interim Chief Executive Officer & Chief Financial Officer, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in New York City on Thursday, September 6, 2018, at 9:35 a.m. ET (Press release, Synthetic Biologics, AUG 30, 2018, View Source [SID1234529194]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the web at View Source After the presentation, a replay will be archived and accessible for 60 days on Synthetic Biologics’ website, www.syntheticbiologics.com.

On August 30, 2018 GTx, Inc. (Nasdaq: GTXI) reported that Robert J. Wills, PhD, Executive Chairman, and other senior executive management team members will present a company overview at the Baird 2018 Global Healthcare Conference on Thursday, September 6, 2018 at 9:05 am ET in New York (Press release, GTx, AUG 30, 2018, View Source;p=irol-newsArticle&ID=2365454 [SID1234529177]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A simultaneous webcast of the presentation can be accessed by visiting the investor relations section of the GTx website at View Source A replay of the presentation will also be available and archived on the site for 30 days.

On August 30, 2018 vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, reported it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, vTv Therapeutics, AUG 30, 2018, View Source [SID1234529195]).The conference is being held September 4-6, 2018, at The St. Regis Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

vTv management will provide an overview of the company’s business during the live presentation at 1:45pm ET on September 6, 2018 in the Fontainebleau Foyer (2nd floor).

A live webcast of the presentation can be accessed here and will be archived for 30 days following the presentation at www.vtvtherapeutics.com.

On August 30, 2018 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, reported that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Wednesday, September 5, 2018, at 10 a.m. EDT (Press release, Checkpoint Therapeutics, AUG 30, 2018, View Source [SID1234529161]). The conference will be held at the St. Regis New York in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Events page of the Investors & Media section of Checkpoint’s website: www.checkpointtx.com.

On August 30, 2018 Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, reported that an overview of the company’s business strategy and commercial and development-stage programs will be given at two upcoming conferences being held in New York on September 5th and September 6th (Press release, Spectrum Pharmaceuticals, AUG 30, 2018, View Source [SID1234529178]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

20th Annual Rodman & Renshaw Global Investment Conference
When: Wednesday, September 5, 2018 at 10:25 AM ET
Baird’s 2018 Global Healthcare Conference
When: Thursday, September 6, 2018 at 1:25 PM ET

The presentations will be webcast live and may be accessed by visiting Spectrum’s website at View Source